162 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
to Section 3(b)(i).
(vii) No Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent … pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement,
(A) a negative assurance letter and the written
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
and there can be no assurance that the IRS or a court will not take a contrary position.
S-14
As used herein, a “U.S. Holder” is a person that, for U.S … be no assurance regarding our PFIC status for the current year or any particular year in the future because PFIC status is factual in nature, depends
10-Q
2024 Q1
EX-31.1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
agreements for its rare disease or oncology product candidates. Although management continues to pursue these plans, there is no assurance
10-Q
2024 Q1
EX-31.2
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
8-K
EX-99.1
nmvnsa5los5
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
10-K
EX-31.1
t4xiafo
27 Mar 24
Annual report
5:20pm
10-K
EX-31.2
5y6oa phrovu
27 Mar 24
Annual report
5:20pm
10-K
aia7k 1od
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
hfjbgwvc8w ht1
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
w0fi xs8w885mbbj9yr
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
19z0p8 qagn9at65ppjb
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
k9xx0kjp0 db91
17 Oct 23
Current report (foreign)
7:01am
6-K
wq2jxi48i a6a4r
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
55cqf9b
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
m3r358wzchbcmv8sah
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
vdwrmctjaw
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
wzq fg6puy0dc0u77rmf
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
5bfj43u z4c1uslo
27 Apr 23
Current report (foreign)
4:15pm
6-K
8dtfld578652
10 Nov 22
Current report (foreign)
4:10pm